Researchers published comprehensive multi‑omic analyses following a gene‑edited pig kidney transplanted into a brain‑dead human recipient and tracked immune responses over 61 days. Teams identified antibody and T‑cell drivers of rejection, mapped shared human‑pig gene expression within the graft, and demonstrated reversal of rejection using an FDA‑approved drug combination. Authors say the data define immune signatures to anticipate and treat xenograft rejection, advancing readiness for living human trials.